CompletedNCT01634542
An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia
Observational studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Buenos Aires and 147 more locationsSee all locations and recruitment
Study information
Study start dateFebruary 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,433
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- France, Canada, United Kingdom, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01634542
- Official title
Show the full official title
A Non-Interventional Prospective Cohort Study of Patients With Persistent Symptoms of Schizophrenia to Describe The Course and Burden of Illness
Get this study by email
Recruitment & locations
CompletedBuenos Aires, Argentina · Caba, Argentina · La Plata, Argentina
122 more locations
- Goiânia, Brazil
- Curitiba, Brazil
- São Paulo, Brazil
- Medicine Hat, Canada
- Vancouver, Canada
- Chatam, Canada
- Mississauga, Canada
- Windsor, Canada
- Montreal, Canada
- Québec, Canada
- Verdun, Canada
- Aix-en-Provence, France
- Chaumont, France
- Colmar, France
- Corbeil-Essonnes, France
- Issy-les-Moulineaux, France
- Lille, France
- Lyon, France
- Marseille, France
- Montberon, France
- Montebeliard, France
- Montpellier, France
- Nantes, France
- Nice, France
- Paris, France
- Poitiers, France
- Rennes, France
- Rouffach, France
- Saint-Cyr-au-Mont-d'Or, France
- Tassin-la-Demi-Lune, France
- Toulouse, France
- Verdun, France
- Aachen, Germany
- Alzey, Germany
- Augsburg, Germany
- Bad Zwischenahn, Germany
- Berlin, Germany
- Bochum, Germany
- Cologne, Germany
- Dortmund, Germany
- Dresden, Germany
- Düsseldorf, Germany
- Ellwangen, Germany
- Essen, Germany
- Grünstadt, Germany
- Halle, Germany
- Hamburg, Germany
- Homburg/Saar, Germany
- Jena, Germany
- Koeln-Pulheim, Germany
- Leipzig, Germany
- Magdeburg, Germany
- Mainz, Germany
- Mannheim, Germany
- Marburg, Germany
- Mittweida, Germany
- Oranienburg, Germany
- Regensburg, Germany
- Rostock, Germany
- Siegen, Germany
- Weinsberg, Germany
- Westerstede, Germany
- Bari, Italy
- Catanzaro, Italy
- Bologna, Italy
- Trieste, Italy
- Udine, Italy
- Rome, Italy
- Genoa, Italy
- Cassina Nuova Di Bollate, Italy
- Gardone V.T., Italy
- Milan, Italy
- Campobasso, Italy
- Bra, Italy
- Novara, Italy
- Cagliari, Italy
- Sassari, Italy
- Catania, Italy
- Messina, Italy
- Palermo, Italy
- Florence, Italy
- Perugia, Italy
- Conegliano, Italy
- Padova, Italy
- Alcoy, Spain
- Almería, Spain
- Manacor, Spain
- Palma de Mallorca, Spain
- Barcelona, Spain
- Terrassa, Spain
- Burgos, Spain
- Santander, Spain
- Torrelavega, Spain
- Granada, Spain
- A Coruña, Spain
- Málaga, Spain
- Pamploma, Spain
- Pamplona, Spain
- Palencia, Spain
- Vigo, Spain
- Langreo, Spain
- Soria, Spain
- Reus, Spain
- Valencia, Spain
- Valladolid, Spain
- Bilbao, Spain
- Vitoria-Gasteiz, Spain
- Belfast, United Kingdom
- Bristol, United Kingdom
- Cambridge, United Kingdom
- Cheshire, United Kingdom
- Cornwall, United Kingdom
- Coventry, United Kingdom
- Essex, United Kingdom
- Glasgow, United Kingdom
- Hemel Hempstead, United Kingdom
- Lincolnshire, United Kingdom
- Norfolk, United Kingdom
- Nottingham, United Kingdom
- Stoke-on-Trent, United Kingdom
- Walsall, United Kingdom
- Wolverhampton, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders